Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: Serial 3-month and 12-month optical coherence tomography study

Coronary Artery Disease

Volumn 24, Issue 5, 2013, Pages 431-439

  Kim, Soo Joong ^a,b   Lee, Hang ^a   Cho, Jin Man ^b   Park, Chang Bum ^b   Kim, Weon ^b   Kato, Koji ^a   Yonetsu, Taishi ^a   Kim, Chong Jin ^b   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

everolimus eluting stent; malapposition; neointimal coverage; optical coherence tomography; zotarolimus eluting stent

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALING; HUMAN; HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THICKNESS; THROMBUS; VASCULAR STENT;

EID: 84880784261     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328362b2e7     Document Type: Article

References (34)

1. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56:S1-S42.
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998-1008.
3. Abbott JD, Voss MR, Nakamura M, Cohen HA, Selzer F, Kip KE, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50:2029-2036.
4. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364:583-591.
5. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, et al. Stent thrombosis after successful sirolimus eluting stent implantation. Circulation 2004; 109:1930-1932.
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435-2441.
7. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193-202.
8. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115:2426-2434.
9. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007; 28:961-967.
10. Takano M, Yamamoto M, Inami S, Murakami D, Seimiya K, Ohba T, et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: do uncovered struts persist? J Am Coll Cardiol 2008; 51:968-969.
11. Farb AM, Burke APM, Kolodgie FDP, Virmani RM. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701-1706.
12. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48:2440-2447.
13. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155:108-113.
14. Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009; 95:1907-1912.
15. Guagliumi G, Musumeci G, Sirbu V, Bezerra HG, Suzuki N, Fiocca L, et al. A prospective, randomized, controlled study using optical coherence tomography to evaluate strut coverage of sirolimus-, paclitaxel-, and zotarolimus-eluting coronary stents in long lesions requiring overlapping. JACC Cardiovasc Interv 2010; 3:531-539.
16. Kim JS, Jang IK, Fan C, Kim TH, Kim JS, Park SM, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009; 2:1240-1247.
17. Guidoin R, Marois Y, Zhang Z, King M, Martin L, Laroche G, et al. The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. ASAIO J 1994; 40:M870-M879.
18. Xie X, Guidoin R, Nutley M, Zhang Z. Fluoropassivation and gelatin sealing of polyester arterial prostheses to skip preclotting and constrain the chronic inflammatory response. J Biomed Mater Res B Appl Biomater 2010; 93: 497-509.
19. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, et al. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging 2011; 28:491-497.
20. Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbæk H, Saunama ki K, et al. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 2011; 32:2454-2463.
21. Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention 2007; 3:128-136.
22. Kume T, Akasaka T, Kawamoto T, Ogasawara Y,Watanabe N, Toyota E, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97:1713-1717.
23. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1201-1205.
24. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107:381-383.
25. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100 (Suppl 2):S36-S44.
26. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52:333-342.
27. Fujii K, Kawasaki D, Oka K, Akahori H, Fukunaga M, Sawada H, et al. Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation. Heart 2011; 97:977-982.
28. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59:1058-1072.
29. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136-146.
30. Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, et al. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv 2010; 3:1220-1228.
31. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, et al. Everolimuseluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011; 58:1844-1854.
32. De Waha A, Cassese S, Park DW, Burzotta F, Byrne R, Tada T, et al. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 2012; 101:461-467.
33. Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimuseluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J 2012; 163:601-607.
34. Murata A, Wallace-Bradley D, Tellez A, Alviar C, Aboodi M, Sheehy A, et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging 2010; 3: 76-84.